SCHEMBL8191896

SCHEMBL8191896

COC1C[C@H](CO)[C@@H](COCc2ccc(Br)cc2)O1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.33
▸ SLC6A2 P23975 1/20 0.33
▸ PDE4D Q08499 1/20 0.33
▸ MAPT P10636 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ CA1 P00915 2/20 0.32
▸ CA2 P00918 2/20 0.32
▸ CA9 Q16790 2/20 0.32
▸ CA12 O43570 1/20 0.32
▸ IDO1 P14902 2/20 0.31
▸ NPSR1 Q6W5P4 2/20 0.31
▸ GJB2 P29033 2/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ GJA1 P17302 1/20 0.31
▸ MAOB P27338 2/20 0.30
▸ CHRM3 P20309 1/20 0.30
▸ MAOA P21397 1/20 0.30
▸ TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10431960 0.78 GJB2 (0.42) SLC6A2PDE4DGJB2
SCHEMBL6763188 0.76 IDO1 (0.41) SLC6A2PDE4DKDM4EIDO1KMT2A
SCHEMBL8193121 0.76 IDO1 (0.41) SLC6A2PDE4DKDM4EIDO1KMT2A
SCHEMBL9146062 0.76 IDO1 (0.41) SLC6A2PDE4DKDM4EIDO1KMT2A
SCHEMBL8192755 0.76 IDO1 (0.41) SLC6A2PDE4DKDM4EIDO1KMT2A
SCHEMBL8193352 0.76 IDO1 (0.41) SLC6A2PDE4DKDM4EIDO1KMT2A
SCHEMBL4953874 0.73 — —
SCHEMBL22992300 0.71 PDE4D (0.48) SLC6A2PDE4DGJB2
SCHEMBL9843718 0.71 PDE4D (0.48) SLC6A2PDE4DGJB2
SCHEMBL9844144 0.71 PDE4D (0.48) SLC6A2PDE4DGJB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6121431-A VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS AND HEPATITIS B VIRUS MEDIVIR AB (SE) 2000-09-19 — — US disclosed
US-5952500-A VIRICIDES CAN BE USED IN THERAPEUTIC AND PROPHYLACTIC TREATMENT OF THE ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), INFECTIONS OF HUMAN IMMUNE DEFICIENCY VIRUSES, HEPATITIS B VIRUS, HERPES VIRUSES AND CANCER MEDIVIR AB (SE) 1999-09-14 — — US disclosed
US-5747473-A L-nucleoside analogues and pharmaceutical compositions MEDIVIR AB (SE) 1998-05-05 — — US disclosed
US-5473063-A Reacting 2,3-epoxy-butanediol/1,4-/(having protected hydroxyl groups) with an alpha allylic nucleophile yields 2-hydroxy-3-allyl-1,4-butanediol, then oxidatively cleaving the double bond, cyclization, halogenation, acetylation or oxyalkylation MEDIVIR AB (SE) 1995-12-05 — — US disclosed
WO-1992006102-A1 NUCLEOSIDE DERIVATIVES MEDIVIR AB (SE) 1992-04-16 — — WO disclosed
Send feedback